Status:
UNKNOWN
Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis
Lead Sponsor:
Lei Li
Conditions:
Adenomyosis
Endometrial Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pa...
Eligibility Criteria
Inclusion
- Pathological confirmed diagnosis with atypical hyperplasia and malignant transformation of adenomyosis glandular epithelium (including endometrioid, serous and clear cell carcinoma), with or without concurrent endometrial carcinoma
- Signed an approved informed consents
Exclusion
- Not meeting all the inclusion criteria.
- The formalin fixed paraffin-embedded (FFPE) tissue was not acquired at the required time period.
- The patients enrolled had accompanied some other kinds of carcinoma (such as ovarian cancer, cervical cancer, primary peritoneal cancer).
- Patients had cancer history of certain organ (such as colorectal cancer, gastric cancer, etc.)
Key Trial Info
Start Date :
July 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04010487
Start Date
July 16 2019
End Date
August 1 2021
Last Update
July 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lei Li
Beijing, Beijing Municipality, China, 100730